Oncodetect On-Demand Recording

Oncodetect On-demand Recording

Watch our Industry Expert Theater session from the 2026 ASCO^® Annual Meeting: Advancing molecular residual disease (MRD) detection: analytics and clinical evidence supporting the Oncodetect^® test, presented by our Chief Medical Officer Rick Baehner, MD, and Senior Principal Medical Affairs Director Jennifer Racz, MD, MBA.

View this recording to learn:

How the Oncodetect test works and its analytical and clinical performance
Next-generation MRD testing approach with whole-genome MAESTRO technology
Findings from the NSABP-59 study and PARTNER MRD sub-study, illustrating the evolving role of MRD testing in breast cancer management

View the recording now

Please complete the form below. All fields are required, unless noted as optional.

Footnotes

This test was developed, and its performance characteristics determined by Genomic Health, Inc. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.

Not an official event of the 2026 ASCO^® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO^®, Association for Clinical Oncology, or Conquer Cancer^®, the ASCO Foundation. Not CME-accredited.

View our latest presentation

View the recording now

Footnotes